查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2152717

AI驅動的臨床試驗解決方案供應商市場規模、佔有率和趨勢分析報告：按治療領域、臨床試驗階段、最終用途、地區和細分市場預測（2026-2033年）

AI-based Clinical Trials Solution Provider Market Size, Share & Trends Analysis Report by Therapeutic Application, By Clinical Trial Phase, By End Use, By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

預計到 2025 年，全球人工智慧 (AI) 驅動的臨床試驗解決方案市場規模將達到 28 億美元，到 2026 年將成長至 35 億美元，到 2033 年將達到 171 億美元，2026 年至 2033 年的複合年成長率為 22.1%。

預計到2025年，北美市場將佔全球銷售額的43.0%以上，成為推動市場成長的主要力量。人工智慧平台在臨床試驗各個階段的日益普及，提高了效率和生產力，也促進了人工智慧臨床試驗解決方案供應商市場的成長。

公共和私營部門在各個治療領域的支持措施對於推動市場成長至關重要。此外，進入市場的公司正在採取多項策略措施來拓展業務。例如，2025年3月，Tempus AI宣布收購Deep 6 AI。此舉旨在透過Deep 6 AI的技術，增強其在招募臨床試驗受試者和產生真實世界數據（REW）方面的能力，並分析涵蓋750多家醫療機構的結構化和非結構化電子健康記錄數據。

由於藥物研發是一個耗時且耗力的過程，在臨床試驗中利用人工智慧可以改善臨床結果、降低成本並縮短所需時間。例如，2025年12月，Accenture宣布透過其創投公司埃森哲創投(Accenture Ventures)對Ryght AI進行策略性投資。 Ryght AI的「AI Site Twin」平台旨在解決臨床試驗流程中存在的挑戰，建立臨床研究中心的數位化模型，並提供對歷史數據、患者人口統計數據和營運數據的即時存取。這些發展對於推動該市場的成長至關重要。

此外，人工智慧在減少醫療數據偏差方面發揮著至關重要的作用。例如，基因泰克公司與史丹佛大學合作，利用開放原始碼人工智慧系統來減輕藥物臨床試驗中的偏差。同時，隨著業界從傳統方法轉向技術驅動型方法，領先的製藥公司擴大在臨床試驗中採用人工智慧，這正在推動市場成長。

此外，人工智慧在藥物臨床試驗中的應用日益廣泛，以及基於人工智慧的解決方案在臨床試驗各個環節（例如患者篩選和入組、臨床實驗試驗設計、研究者和研究中心選擇、用藥依從性以及病患監測）的普及，正在推動市場成長。病患合格評估和入組是藥物臨床試驗整體成功的關鍵步驟。研究表明，85%的藥物臨床試驗在患者招募階段停滯不前，30%的試驗因招募失敗而提前終止。基於人工智慧的平台有助於克服這些障礙。因此，許多研究人員正在藥物臨床試驗中應用人工智慧，推動市場成長。

目錄

第1章：調查方法和範圍

第2章執行摘要

第3章 市場：變數、趨勢與範圍

  • 市場譜系展望
  • 市場動態
  • 臨床試驗解決方案供應商的AI驅動型市場分析工具
  • 案例研究

第4章：人工智慧驅動的臨床試驗解決方案供應商市場：按治療領域分類的估算和趨勢分析

  • 按治療應用分類的趨勢分析、市場佔有率分析（2025 年和 2033 年）
  • 全球人工智慧驅動的臨床試驗解決方案供應商市場：按治療領域分類的展望
  • 腫瘤學
  • CVD
  • 神經系統疾病或病症
  • 代謝性疾病
  • 感染疾病
  • 其他

第5章：人工智慧驅動的臨床試驗解決方案供應商市場：臨床試驗階段估算與趨勢分析

  • 臨床試驗階段變化分析與市佔率分析（2025 年和 2033 年）
  • 全球人工智慧驅動的臨床試驗解決方案供應商市場：按臨床試驗階段分類的展望
  • 第一階段
  • 第二階段
  • 第三階段

第6章：人工智慧驅動的臨床試驗解決方案供應商市場：按最終用途分類的估算和趨勢分析

  • 最終用途趨勢分析、市佔率分析（2025 年和 2033 年）
  • 全球人工智慧驅動型臨床試驗解決方案供應商市場：基於應用的展望
  • 製藥公司
  • 學術機構
  • 其他

第7章：人工智慧驅動的臨床試驗解決方案供應商市場：區域估算與趨勢分析、治療領域、臨床試驗階段和最終用途

  • 2025年及2033年區域市佔率分析
  • 區域市場概覽
  • 全球市場概述（按地區分類）
  • 市場規模、預測與趨勢分析，2021-2033年
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • UAE
    • 科威特

第8章 競爭情勢

  • 主要市場參與企業近期趨勢及影響分析
  • 公司和競爭對手的分類
  • 主要公司市佔率及市場狀況分析（2025 年）
  • 公司簡介
    • Unlearn.ai, Inc.
    • Saama
    • Antidote Technologies, Inc.
    • Phesi
    • Deep6.ai
    • Innoplexus
    • Mendel Health Inc.
    • Intelligencia AI
    • Median Technologies
    • SymphonyAI
    • BioAge Labs, Inc.
    • AiCure
    • Consilx
    • DeepLens.AI
    • HaloHealth
    • PHARMASEAL
    • Ardigen
    • Trials.ai
    • Koneksa Health
    • Euretos
    • BioSymetrics, Inc.
    • Verily（Google LLC）
    • Aitia
    • IBM
    • Exscientia
Product Code: GVR-4-68039-456-6

The global AI-based clinical trials solution provider market size was valued at USD 2.8 billion in 2025 and is projected to grow from USD 3.5 billion in 2026 to USD 17.1 billion by 2033, at a CAGR of 22.1% from 2026 to 2033. The North America market dominated with a revenue share of more than 43.0% in 2025. The growing adoption of AI-based platforms to enhance the efficacy and productivity of trials at various stages drives the market for AI-based clinical trial solution providers.

Supportive initiatives by the public and private sectors for different therapeutic areas are crucial in driving market growth. Furthermore, market players undertake several strategic initiatives to expand in the market. For instance, in March 2025, Tempus AI announced the acquisition of Deep 6 AI, aiming to expand its capabilities in clinical trial recruitment and real-world evidence generation through Deep 6 AI's technology and analyze structured and unstructured electronic medical record data across a network of more than 750 provider sites.

Using AI in drug trials enhances the clinical outcomes, cost, and time required for drug trials, as drug development is a cost-intensive and time-consuming process. For instance, in December 2025, Accenture announced a strategic investment through Accenture Ventures in Ryght AI. While addressing existing challenges in clinical trial processes, Rhyght AI's AI Site Twin platform develops digital models of clinical research sites, accessing historical performance, patient demographics, and operational data in real time. Such developments are key to the growth of this market.

Moreover, AI is instrumental in reducing bias in medical data. For instance, Genentech partnered with Stanford University to employ an open-source AI system to mitigate bias in drug trials. In addition, as the industry shifts from traditional to technology-based approaches, major pharmaceutical companies are increasingly adopting AI in clinical trials, thereby driving market growth.

Furthermore, the rising penetration of AI in drug trials and the availability of AI-based solutions in different aspects of clinical trials, such as patient enrichment & enrollment, drug trial design, investigator & site selection, medication adherence, and patient monitoring, among others, are fueling the market growth. Patient eligibility and enrollment are some of the important steps for the success of the overall drug trial. As per the research, 85% of the drug trials are stalled during patient recruitment, and 30% end early due to recruitment failure. The AI-based platforms are beneficial in lowering this hindrance. Hence, numerous researchers use AI for drug trials, fostering market growth.

Global AI-based Clinical Trials Solution Provider Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global AI-based clinical trials solution provider market report based on therapeutic applications, clinical trial phase, end use, and region:

  • Therapeutic Applications Outlook (Revenue, USD Billion, 2021 - 2033)

Oncology

CVD

Neurological Diseases or conditions

Metabolic diseases

Infectious diseases

Others

  • Clinical Trial Phase (Revenue, USD Billion, 2021 - 2033)

Phase-I

Phase-II

Phase-III

  • End Use Outlook (Revenue, USD Billion, 2021 - 2033)

Pharmaceutical Companies

Academia

Others

  • Regional Outlook (Revenue, USD Billion, 2021 - 2033)

North America

    • U.S.
    • Canada
    • Mexico

Europe

    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway

Asia Pacific

    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand

Latin America

    • Brazil
    • Argentina

Middle East & Africa

    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Therapeutic applications
    • 1.1.2. Clinical trial phase
    • 1.1.3. End use
    • 1.1.4. Regional scope
    • 1.1.5. Estimates and forecast timeline.
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database.
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity flow analysis (Model 1)
    • 1.6.2. Approach 1: Commodity flow approach
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Therapeutic applications outlook
    • 2.2.2. Clinical trial phase outlook
    • 2.2.3. End use outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. AI-Based Clinical Trials Solution Providers Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic landscape
      • 3.3.2.3. Social landscape
      • 3.3.2.4. Technological landscape
      • 3.3.2.5. Environmental landscape
      • 3.3.2.6. Legal landscape
    • 3.3.3. COVID-19 Impact
  • 3.4. Case Studies

Chapter 4. AI-Based Clinical Trials Solution Providers Market: Therapeutic Applications Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Therapeutic Applications Movement & Market Share Analysis, 2025 & 2033
  • 4.3. Global AI-Based Clinical Trials Solution Providers Market by Therapeutic Applications Outlook
  • 4.4. Oncology
    • 4.4.1. Market estimates and forecast 2021 to 2033 (USD Million)
  • 4.5. CVD
    • 4.5.1. Market estimates and forecast 2021 to 2033 (USD Million) CVD
  • 4.6. Neurological Diseases or Conditions
    • 4.6.1. Market estimates and forecast 2021 to 2033 (USD Million)
  • 4.7. Metabolic Diseases
    • 4.7.1. Market estimates and forecast 2021 to 2033 (USD Million)
  • 4.8. Infectious Diseases
    • 4.8.1. Market estimates and forecast 2021 to 2033 (USD Million)
  • 4.9. Others
    • 4.9.1. Market estimates and forecast 2021 to 2033 (USD Million)

Chapter 5. AI-Based Clinical Trials Solution Providers Market: Clinical Trial Phase Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Clinical Trial Phase Movement & Market Share Analysis, 2025 & 2033
  • 5.3. Global AI-Based Clinical Trials Solution Providers Market by Clinical Trial Phase Outlook
  • 5.4. Phase-I
    • 5.4.1. Market estimates and forecast 2021 to 2033 (USD Million)
  • 5.5. Phase-II
    • 5.5.1. Market estimates and forecast 2021 to 2033 (USD Million)
  • 5.6. Phase-III
    • 5.6.1. Market estimates and forecast 2021 to 2033 (USD Million)

Chapter 6. AI-Based Clinical Trials Solution Providers Market: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. End Use Movement & Market Share Analysis, 2025 & 2033
  • 6.3. Global AI-Based Clinical Trials Solution Providers Market by End Use Outlook
  • 6.4. Pharmaceutical Companies
    • 6.4.1. Market estimates and forecast 2021 to 2033 (USD Million)
  • 6.5. Academia
    • 6.5.1. Market estimates and forecast 2021 to 2033 (USD Million)
  • 6.6. Others
    • 6.6.1. Market estimates and forecast 2021 to 2033 (USD Million)

Chapter 7. AI-Based Clinical Trials Solution Providers Market: Regional Estimates & Trend Analysis, By Therapeutic Applications, By Clinical Trial Phase, By End Use

  • 7.1. Regional Market Share Analysis, 2025 & 2033
  • 7.2. Regional Market Dashboard
  • 7.3. Global Regional Market Snapshot
  • 7.4. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
  • 7.5. North America
    • 7.5.1. U.S.
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.2. Canada
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6. Europe
    • 7.6.1. UK
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.2. Germany
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.3. France
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Regulatory framework/ reimbursement structure
      • 7.6.3.3. Competitive scenario
      • 7.6.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.4. Italy
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Regulatory framework/ reimbursement structure
      • 7.6.4.3. Competitive scenario
      • 7.6.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.5. Spain
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Regulatory framework/ reimbursement structure
      • 7.6.5.3. Competitive scenario
      • 7.6.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.6. Norway
      • 7.6.6.1. Key country dynamics
      • 7.6.6.2. Regulatory framework/ reimbursement structure
      • 7.6.6.3. Competitive scenario
      • 7.6.6.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.7. Sweden
      • 7.6.7.1. Key country dynamics
      • 7.6.7.2. Regulatory framework/ reimbursement structure
      • 7.6.7.3. Competitive scenario
      • 7.6.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.8. Denmark
      • 7.6.8.1. Key country dynamics
      • 7.6.8.2. Regulatory framework/ reimbursement structure
      • 7.6.8.3. Competitive scenario
      • 7.6.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7. Asia Pacific
    • 7.7.1. Japan
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.2. China
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.3. India
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.4. Australia
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.5. South Korea
      • 7.7.5.1. Key country dynamics
      • 7.7.5.2. Regulatory framework/ reimbursement structure
      • 7.7.5.3. Competitive scenario
      • 7.7.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.6. Thailand
      • 7.7.6.1. Key country dynamics
      • 7.7.6.2. Regulatory framework/ reimbursement structure
      • 7.7.6.3. Competitive scenario
      • 7.7.6.4. Singapore market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.8. Latin America
    • 7.8.1. Brazil
      • 7.8.1.1. Key country dynamics
      • 7.8.1.2. Regulatory framework/ reimbursement structure
      • 7.8.1.3. Competitive scenario
      • 7.8.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.8.2. Mexico
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Regulatory framework/ reimbursement structure
      • 7.8.2.3. Competitive scenario
      • 7.8.2.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.8.3. Argentina
      • 7.8.3.1. Key country dynamics
      • 7.8.3.2. Regulatory framework/ reimbursement structure
      • 7.8.3.3. Competitive scenario
      • 7.8.3.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.9. MEA
    • 7.9.1. South Africa
      • 7.9.1.1. Key country dynamics
      • 7.9.1.2. Regulatory framework/ reimbursement structure
      • 7.9.1.3. Competitive scenario
      • 7.9.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.9.2. Saudi Arabia
      • 7.9.2.1. Key country dynamics
      • 7.9.2.2. Regulatory framework/ reimbursement structure
      • 7.9.2.3. Competitive scenario
      • 7.9.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.9.3. UAE
      • 7.9.3.1. Key country dynamics
      • 7.9.3.2. Regulatory framework/ reimbursement structure
      • 7.9.3.3. Competitive scenario
      • 7.9.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.9.4. Kuwait
      • 7.9.4.1. Key country dynamics
      • 7.9.4.2. Regulatory framework/ reimbursement structure
      • 7.9.4.3. Competitive scenario
      • 7.9.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Key company market share/position analysis, 2025
  • 8.4. Company Profiles
    • 8.4.1. Unlearn.ai, Inc.
      • 8.4.1.1. Company overview
      • 8.4.1.2. Financial performance
      • 8.4.1.3. Technology Type benchmarking
      • 8.4.1.4. Strategic initiatives
    • 8.4.2. Saama
      • 8.4.2.1. Company overview
      • 8.4.2.2. Financial performance
      • 8.4.2.3. Technology Type benchmarking
      • 8.4.2.4. Strategic initiatives
    • 8.4.3. Antidote Technologies, Inc.
      • 8.4.3.1. Company overview
      • 8.4.3.2. Financial performance
      • 8.4.3.3. Technology Type benchmarking
      • 8.4.3.4. Strategic initiatives
    • 8.4.4. Phesi
      • 8.4.4.1. Company overview
      • 8.4.4.2. Financial performance
      • 8.4.4.3. Technology Type benchmarking
      • 8.4.4.4. Strategic initiatives
    • 8.4.5. Deep6.ai
      • 8.4.5.1. Company overview
      • 8.4.5.2. Financial performance
      • 8.4.5.3. Technology Type benchmarking
      • 8.4.5.4. Strategic initiatives
    • 8.4.6. Innoplexus
      • 8.4.6.1. Company overview
      • 8.4.6.2. Financial performance
      • 8.4.6.3. Technology Type benchmarking
      • 8.4.6.4. Strategic initiatives
    • 8.4.7. Mendel Health Inc.
      • 8.4.7.1. Company overview
      • 8.4.7.2. Financial performance
      • 8.4.7.3. Technology Type benchmarking
      • 8.4.7.4. Strategic initiatives
    • 8.4.8. Intelligencia AI
      • 8.4.8.1. Company overview
      • 8.4.8.2. Financial performance
      • 8.4.8.3. Technology Type benchmarking
      • 8.4.8.4. Strategic initiatives
    • 8.4.9. Median Technologies
      • 8.4.9.1. Company overview
      • 8.4.9.2. Financial performance
      • 8.4.9.3. Technology Type benchmarking
      • 8.4.9.4. Strategic initiatives
    • 8.4.10. SymphonyAI
      • 8.4.10.1. Company overview
      • 8.4.10.2. Financial performance
      • 8.4.10.3. Technology Type benchmarking
      • 8.4.10.4. Strategic initiatives
    • 8.4.11. BioAge Labs, Inc.
      • 8.4.11.1. Company overview
      • 8.4.11.2. Financial performance
      • 8.4.11.3. Technology Type benchmarking
      • 8.4.11.4. Strategic initiatives
    • 8.4.12. AiCure
      • 8.4.12.1. Company overview
      • 8.4.12.2. Financial performance
      • 8.4.12.3. Technology Type benchmarking
      • 8.4.12.4. Strategic initiatives
    • 8.4.13. Consilx
      • 8.4.13.1. Company overview
      • 8.4.13.2. Financial performance
      • 8.4.13.3. Technology Type benchmarking
      • 8.4.13.4. Strategic initiatives
    • 8.4.14. DeepLens.AI
      • 8.4.14.1. Company overview
      • 8.4.14.2. Financial performance
      • 8.4.14.3. Technology Type benchmarking
      • 8.4.14.4. Strategic initiatives
    • 8.4.15. HaloHealth
      • 8.4.15.1. Company overview
      • 8.4.15.2. Financial performance
      • 8.4.15.3. Technology Type benchmarking
      • 8.4.15.4. Strategic initiatives
    • 8.4.16. PHARMASEAL
      • 8.4.16.1. Company overview
      • 8.4.16.2. Financial performance
      • 8.4.16.3. Technology Type benchmarking
      • 8.4.16.4. Strategic initiatives
    • 8.4.17. Ardigen
      • 8.4.17.1. Company overview
      • 8.4.17.2. Financial performance
      • 8.4.17.3. Technology Type benchmarking
      • 8.4.17.4. Strategic initiatives
    • 8.4.18. Trials.ai
      • 8.4.18.1. Company overview
      • 8.4.18.2. Financial performance
      • 8.4.18.3. Technology Type benchmarking
      • 8.4.18.4. Strategic initiatives
    • 8.4.19. Koneksa Health
      • 8.4.19.1. Company overview
      • 8.4.19.2. Financial performance
      • 8.4.19.3. Technology Type benchmarking
      • 8.4.19.4. Strategic initiatives
    • 8.4.20. Euretos
      • 8.4.20.1. Company overview
      • 8.4.20.2. Financial performance
      • 8.4.20.3. Technology Type benchmarking
      • 8.4.20.4. Strategic initiatives
    • 8.4.21. BioSymetrics, Inc.
      • 8.4.21.1. Company overview
      • 8.4.21.2. Financial performance
      • 8.4.21.3. Technology Type benchmarking
      • 8.4.21.4. Strategic initiatives
    • 8.4.22. Verily (Google LLC)
      • 8.4.22.1. Company overview
      • 8.4.22.2. Financial performance
      • 8.4.22.3. Technology Type benchmarking
      • 8.4.22.4. Strategic initiatives
    • 8.4.23. Aitia
      • 8.4.23.1. Company overview
      • 8.4.23.2. Financial performance
      • 8.4.23.3. Technology Type benchmarking
      • 8.4.23.4. Strategic initiatives
    • 8.4.24. IBM
      • 8.4.24.1. Company overview
      • 8.4.24.2. Financial performance
      • 8.4.24.3. Technology Type benchmarking
      • 8.4.24.4. Strategic initiatives
    • 8.4.25. Exscientia
      • 8.4.25.1. Company overview
      • 8.4.25.2. Financial performance
      • 8.4.25.3. Technology Type benchmarking
      • 8.4.25.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America AI-based clinical trials solution providers market, by region, 2021 - 2033 (USD Million)
  • Table 3 North America AI-based clinical trials solution providers market, by therapeutic applications, 2021 - 2033 (USD Million)
  • Table 4 North America AI-based clinical trials solution providers market, by clinical trial phase, 2021 - 2033 (USD Million)
  • Table 5 North America AI-based clinical trials solution providers market, by end use, 2021 - 2033 (USD Million)
  • Table 6 U.S. AI-based clinical trials solution providers market, by therapeutic applications, 2021 - 2033 (USD Million)
  • Table 7 U.S. AI-based clinical trials solution providers market, by clinical trial phase, 2021 - 2033 (USD Million)
  • Table 8 U.S. AI-based clinical trials solution providers market, by end use, 2021 - 2033 (USD Million)
  • Table 9 Canada AI-based clinical trials solution providers market, by therapeutic applications, 2021 - 2033 (USD Million)
  • Table 10 Canada AI-based clinical trials solution providers market, by clinical trial phase, 2021 - 2033 (USD Million)
  • Table 11 Canada AI-based clinical trials solution providers market, by end use, 2021 - 2033 (USD Million)
  • Table 12 Europe AI-based clinical trials solution providers market, by region, 2021 - 2033 (USD Million)
  • Table 13 Europe AI-based clinical trials solution providers market, by therapeutic applications, 2021 - 2033 (USD Million)
  • Table 14 Europe AI-based clinical trials solution providers market, by clinical trial phase, 2021 - 2033 (USD Million)
  • Table 15 Europe AI-based clinical trials solution providers market, by end use, 2021 - 2033 (USD Million)
  • Table 16 Germany AI-based clinical trials solution providers market, by therapeutic applications, 2021 - 2033 (USD Million)
  • Table 17 Germany AI-based clinical trials solution providers market, by clinical trial phase, 2021 - 2033 (USD Million)
  • Table 18 Germany AI-based clinical trials solution providers market, by end use, 2021 - 2033 (USD Million)
  • Table 19 UK AI-based clinical trials solution providers market, by therapeutic applications, 2021 - 2033 (USD Million)
  • Table 20 UK AI-based clinical trials solution providers market, by clinical trial phase, 2021 - 2033 (USD Million)
  • Table 21 UK AI-based clinical trials solution providers market, by end use, 2021 - 2033 (USD Million)
  • Table 22 France AI-based clinical trials solution providers market, by therapeutic applications, 2021 - 2033 (USD Million)
  • Table 23 France AI-based clinical trials solution providers market, by clinical trial phase, 2021 - 2033 (USD Million)
  • Table 24 France AI-based clinical trials solution providers market, by end use, 2021 - 2033 (USD Million)
  • Table 25 Italy AI-based clinical trials solution providers market, by therapeutic applications, 2021 - 2033 (USD Million)
  • Table 26 Italy AI-based clinical trials solution providers market, by clinical trial phase, 2021 - 2033 (USD Million)
  • Table 27 Italy AI-based clinical trials solution providers market, by end use, 2021 - 2033 (USD Million)
  • Table 28 Spain AI-based clinical trials solution providers market, by therapeutic applications, 2021 - 2033 (USD Million)
  • Table 29 Spain AI-based clinical trials solution providers market, by clinical trial phase, 2021 - 2033 (USD Million)
  • Table 30 Spain AI-based clinical trials solution providers market, by end use, 2021 - 2033 (USD Million)
  • Table 31 Denmark AI-based clinical trials solution providers market, by therapeutic applications, 2021 - 2033 (USD Million)
  • Table 32 Denmark AI-based clinical trials solution providers market, by clinical trial phase, 2021 - 2033 (USD Million)
  • Table 33 Denmark AI-based clinical trials solution providers market, by end use, 2021 - 2033 (USD Million)
  • Table 34 Sweden AI-based clinical trials solution providers market, by therapeutic applications, 2021 - 2033 (USD Million)
  • Table 35 Sweden AI-based clinical trials solution providers market, by clinical trial phase, 2021 - 2033 (USD Million)
  • Table 36 Sweden AI-based clinical trials solution providers market, by end use, 2021 - 2033 (USD Million)
  • Table 37 Norway AI-based clinical trials solution providers market, by therapeutic applications, 2021 - 2033 (USD Million)
  • Table 38 Norway AI-based clinical trials solution providers market, by clinical trial phase, 2021 - 2033 (USD Million)
  • Table 39 Norway AI-based clinical trials solution providers market, by end use, 2021 - 2033 (USD Million)
  • Table 40 Asia Pacific AI-based clinical trials solution providers market, by region, 2021 - 2033 (USD Million)
  • Table 41 Asia Pacific AI-based clinical trials solution providers market, by therapeutic applications, 2021 - 2033 (USD Million)
  • Table 42 Asia Pacific AI-based clinical trials solution providers market, by clinical trial phase, 2021 - 2033 (USD Million)
  • Table 43 Asia Pacific AI-based clinical trials solution providers market, by end use, 2021 - 2033 (USD Million)
  • Table 44 China AI-based clinical trials solution providers market, by therapeutic applications, 2021 - 2033 (USD Million)
  • Table 45 China AI-based clinical trials solution providers market, by clinical trial phase, 2021 - 2033 (USD Million)
  • Table 46 China AI-based clinical trials solution providers market, by end use, 2021 - 2033 (USD Million)
  • Table 47 Japan AI-based clinical trials solution providers market, by therapeutic applications, 2021 - 2033 (USD Million)
  • Table 48 Japan AI-based clinical trials solution providers market, by clinical trial phase, 2021 - 2033 (USD Million)
  • Table 49 Japan AI-based clinical trials solution providers market, by end use, 2021 - 2033 (USD Million)
  • Table 50 India AI-based clinical trials solution providers market, by therapeutic applications, 2021 - 2033 (USD Million)
  • Table 51 India AI-based clinical trials solution providers market, by clinical trial phase, 2021 - 2033 (USD Million)
  • Table 52 India AI-based clinical trials solution providers market, by end use, 2021 - 2033 (USD Million)
  • Table 53 South Korea AI-based clinical trials solution providers market, by therapeutic applications, 2021 - 2033 (USD Million)
  • Table 54 South Korea AI-based clinical trials solution providers market, by clinical trial phase, 2021 - 2033 (USD Million)
  • Table 55 South Korea AI-based clinical trials solution providers market, by end use, 2021 - 2033 (USD Million)
  • Table 56 Australia AI-based clinical trials solution providers market, by therapeutic applications, 2021 - 2033 (USD Million)
  • Table 57 Australia AI-based clinical trials solution providers market, by clinical trial phase, 2021 - 2033 (USD Million)
  • Table 58 Australia AI-based clinical trials solution providers market, by end use, 2021 - 2033 (USD Million)
  • Table 59 Thailand AI-based clinical trials solution providers market, by therapeutic applications, 2021 - 2033 (USD Million)
  • Table 60 Thailand AI-based clinical trials solution providers market, by clinical trial phase, 2021 - 2033 (USD Million)
  • Table 61 Thailand AI-based clinical trials solution providers market, by end use, 2021 - 2033 (USD Million)
  • Table 62 Latin America AI-based clinical trials solution providers market, by region, 2021 - 2033 (USD Million)
  • Table 63 Latin America AI-based clinical trials solution providers market, by therapeutic applications, 2021 - 2033 (USD Million)
  • Table 64 Latin America AI-based clinical trials solution providers market, by clinical trial phase, 2021 - 2033 (USD Million)
  • Table 65 Latin America AI-based clinical trials solution providers market, by end use, 2021 - 2033 (USD Million)
  • Table 66 Brazil AI-based clinical trials solution providers market, by therapeutic applications, 2021 - 2033 (USD Million)
  • Table 67 Brazil AI-based clinical trials solution providers market, by clinical trial phase, 2021 - 2033 (USD Million)
  • Table 68 Brazil AI-based clinical trials solution providers market, by end use, 2021 - 2033 (USD Million)
  • Table 69 Argentina AI-based clinical trials solution providers market, by therapeutic applications, 2021 - 2033 (USD Million)
  • Table 70 Argentina AI-based clinical trials solution providers market, by clinical trial phase, 2021 - 2033 (USD Million)
  • Table 71 Argentina AI-based clinical trials solution providers market, by end use, 2021 - 2033 (USD Million)
  • Table 72 Mexico AI-based clinical trials solution providers market, by therapeutic applications, 2021 - 2033 (USD Million)
  • Table 73 Mexico AI-based clinical trials solution providers market, by clinical trial phase, 2021 - 2033 (USD Million)
  • Table 74 Mexico AI-based clinical trials solution providers market, by end use, 2021 - 2033 (USD Million)
  • Table 75 MEA AI-based clinical trials solution providers market, by region, 2021 - 2033 (USD Million)
  • Table 76 MEA AI-based clinical trials solution providers market, by therapeutic applications, 2021 - 2033 (USD Million)
  • Table 77 MEA AI-based clinical trials solution providers market, by clinical trial phase, 2021 - 2033 (USD Million)
  • Table 78 MEA AI-based clinical trials solution providers market, by end use, 2021 - 2033 (USD Million)
  • Table 79 South Africa AI-based clinical trials solution providers market, by therapeutic applications, 2021 - 2033 (USD Million)
  • Table 80 South Africa AI-based clinical trials solution providers market, by clinical trial phase, 2021 - 2033 (USD Million)
  • Table 81 South Africa AI-based clinical trials solution providers market, by end use, 2021 - 2033 (USD Million)
  • Table 82 Saudi Arabia AI-based clinical trials solution providers market, by therapeutic applications, 2021 - 2033 (USD Million)
  • Table 83 Saudi Arabia AI-based clinical trials solution providers market, by clinical trial phase, 2021 - 2033 (USD Million)
  • Table 84 Saudi Arabia AI-based clinical trials solution providers market, by end use, 2021 - 2033 (USD Million)
  • Table 85 UAE AI-based clinical trials solution providers market, by therapeutic applications, 2021 - 2033 (USD Million)
  • Table 86 UAE AI-based clinical trials solution providers market, by clinical trial phase, 2021 - 2033 (USD Million)
  • Table 87 UAE AI-based clinical trials solution providers market, by end use, 2021 - 2033 (USD Million)
  • Table 88 Kuwait AI-based clinical trials solution providers market, by therapeutic applications, 2021 - 2033 (USD Million)
  • Table 89 Kuwait AI-based clinical trials solution providers market, by clinical trial phase, 2021 - 2033 (USD Million)
  • Table 90 Kuwait AI-based clinical trials solution providers market, by end use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 AI-Based Clinical Trials Solution Providers market: market outlook
  • Fig. 9 AI-Based Clinical Trials Solution Providers competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 AI-Based Clinical Trials Solution Providers market driver impact
  • Fig. 15 AI-Based Clinical Trials Solution Providers market restraint impact
  • Fig. 16 AI-Based Clinical Trials Solution Providers market strategic initiatives analysis
  • Fig. 17 AI-Based Clinical Trials Solution Providers market: Therapeutic applications movement analysis
  • Fig. 18 AI-Based Clinical Trials Solution Providers market: Therapeutic applications outlook and key takeaways
  • Fig. 19 Oncology market estimates and forecast, 2021 - 2033
  • Fig. 20 CVD market estimates and forecast, 2021 - 2033
  • Fig. 21 Neurological diseases or conditions market estimates and forecast, 2021 - 2033
  • Fig. 22 Metabolic diseases market estimates and forecast, 2021 - 2033
  • Fig. 23 Infectious diseases market estimates and forecast, 2021 - 2033
  • Fig. 24 Others market estimates and forecast, 2021 - 2033
  • Fig. 25 AI-Based Clinical Trials Solution Providers market: Clinical trial phase analysis
  • Fig. 26 AI-Based Clinical Trials Solution Providers market: Clinical trial phase outlook and key takeaways
  • Fig. 27 Phase-I market estimates and forecast, 2021 - 2033
  • Fig. 28 Phase-II market estimates and forecast, 2021 - 2033
  • Fig. 29 Phase-III market estimates and forecast, 2021 - 2033
  • Fig. 30 AI-Based Clinical Trials Solution Providers market: End use movement analysis
  • Fig. 31 AI-Based Clinical Trials Solution Providers market: End use outlook and key takeaways
  • Fig. 32 Pharmaceutical companies market estimates and forecast, 2021 - 2033
  • Fig. 33 Academia market estimates and forecast, 2021 - 2033
  • Fig. 34 Others market estimates and forecast, 2021 - 2033
  • Fig. 35 Global AI-based clinical trials solution providers market: Regional movement analysis
  • Fig. 36 Global AI-based clinical trials solution providers market: Regional outlook and key takeaways
  • Fig. 37 Global AI-based clinical trials solution providers market share and leading players
  • Fig. 38 North America market share and leading players
  • Fig. 39 Europe market share and leading players
  • Fig. 40 Asia Pacific market share and leading players
  • Fig. 41 Latin America market share and leading players
  • Fig. 42 Middle East & Africa market share and leading players
  • Fig. 43 North America: SWOT
  • Fig. 44 Europe SWOT
  • Fig. 45 Asia Pacific SWOT
  • Fig. 46 Latin America SWOT
  • Fig. 47 MEA SWOT
  • Fig. 48 North America market estimates and forecasts, 2021 - 2033
  • Fig. 49 U.S. market estimates and forecasts, 2021 - 2033
  • Fig. 50 Canada market estimates and forecasts, 2021 - 2033
  • Fig. 51 Europe market estimates and forecasts, 2021 - 2033
  • Fig. 52 UK market estimates and forecasts, 2021 - 2033
  • Fig. 53 Germany market estimates and forecasts, 2021 - 2033
  • Fig. 54 France market estimates and forecasts, 2021 - 2033
  • Fig. 55 Italy market estimates and forecasts, 2021 - 2033
  • Fig. 56 Spain market estimates and forecasts, 2021 - 2033
  • Fig. 57 Denmark market estimates and forecasts, 2021 - 2033
  • Fig. 58 Sweden market estimates and forecasts, 2021 - 2033
  • Fig. 59 Norway market estimates and forecasts, 2021 - 2033
  • Fig. 60 Asia Pacific market estimates and forecasts, 2021 - 2033
  • Fig. 61 China market estimates and forecasts, 2021 - 2033
  • Fig. 62 Japan market estimates and forecasts, 2021 - 2033
  • Fig. 63 India market estimates and forecasts, 2021 - 2033
  • Fig. 64 Thailand market estimates and forecasts, 2021 - 2033
  • Fig. 65 South Korea market estimates and forecasts, 2021 - 2033
  • Fig. 66 Australia market estimates and forecasts, 2021 - 2033
  • Fig. 67 Latin America market estimates and forecasts, 2021 - 2033
  • Fig. 68 Brazil market estimates and forecasts, 2021 - 2033
  • Fig. 69 Mexico market estimates and forecasts, 2021 - 2033
  • Fig. 70 Argentina market estimates and forecasts, 2021 - 2033
  • Fig. 71 Middle East and Africa market estimates and forecasts, 2021 - 2033
  • Fig. 72 South Africa market estimates and forecasts, 2021 - 2033
  • Fig. 73 Saudi Arabia market estimates and forecasts, 2021 - 2033
  • Fig. 74 UAE market estimates and forecasts, 2021 - 2033
  • Fig. 75 Kuwait market estimates and forecasts, 2021 - 2033
  • Fig. 76 Company Categorization
  • Fig. 77 Company market position/share analysis
  • Fig. 78 Strategic Framework